You are here:

Forthcoming Submission: everolimus (Votubia)

Indication: Adjunctive treatment of patients aged 2 years and older whose refractory partial -onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex.

Drug Details

Drug Name: everolimus (Votubia)
Drug Manufacturer: Novartis Pharmaceuticals UK Ltd
BNF Category:
Submission type: Full submission
Patient Interest Group
Submission Deadline:
5/03/2018
SMC Meeting Date: Q2 2018
Advice Due: Q2 2018

Back